Why is Novo Nordisk stock sliding today?

Novo Nordisk (NYSE:NVO) submitted its oral Wegovy pill for regulatory review in China, trading at $45.88. Eli Lilly (NYSE:LLY) had previously submitted its rival pill. China's market for obesity treatments is expected to grow significantly. Novo has not disclosed approval or launch timelines. The stock trades 58.04% below its GF Value.

Deutsche Bank downgraded Novo Nordisk (NYSE:NVO) (CSE:NOVOb) to Sell, cutting its price target by 9% to 265 Danish crowns. The move follows mixed Q2 earnings and concerns over growth, particularly for the Wegovy pill and next-gen obesity drug. Shares fell over 3% in Copenhagen trading. The bank cited high-single-digit mid-term revenue cuts and persistent growth concerns. This is the second downgrade from Deutsche Bank this year. Novo Nordisk raised its full-year profit and sales outlook but miss

Novo Nordisk applied for China approval of its oral Wegovy weight-loss drug, aiming to compete with Eli Lilly in the second-largest pharma market. Both companies believe oral drugs may attract patients hesitant about injections. Novo Nordisk's Wegovy pill was approved in the U.S. and UK, while Eli Lilly's oral drug orforglipron was approved in the U.S. in April.

Novo Nordisk (NVO) announced China's approval of its Wegovy weight management tablets, expanding its obesity care portfolio. The company offers a 3.8% dividend yield with a 50% payout ratio and 27.8% dividend growth over three years. NVO's GF Value™ suggests a 56.3% undervaluation, with a GF Score™ of 79/100. Institutional interest remains strong, though some gurus have trimmed positions.

Novo Nordisk's application for oral Wegovy was accepted by China's drug regulator. The Danish company aims to compete with Eli Lilly in China's growing weight-loss drug market. Novo's U.S. and UK approvals for the pill were earlier. Lilly's oral drug may launch in China this year. GLP-1 therapy sales in China could reach $4.46B in 5-7 years, per J.P. Morgan.

Novo Nordisk (NVO) shares rose 3.5% after JPMorgan increased its price target, citing strong Ozempic demand and Wegovy growth. The company recently raised its 2026 outlook, and weekly prescription data showed oral Wegovy reaching a new high. Institutional investors have made significant changes to their NVO positions.